Generative Tensorial Networks
The AI engine Fit Assessment
BetaGTN effectively utilizes machine learning and pattern discovery to innovate drug discovery, expanding therapeutics and optimizing the process.
Blurb
GTN innovates a quantum machine learning technology to transform drug discovery.
HQ Location
London (United Kingdom)
Founded
2017
Employees
11 - 50
Total funding raised
$2.84M
Last Funding Event
Seed, November 1, 2018
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
- Drug Discovery Optimization
Provider of a drug discovery platform intended to transform drug discovery through interdisciplinary innovation. The company's platform combines quantum physics and machine learning algorithms to transform the search and discovery of patient-centered drugs, enabling researchers to discover new medicines that are more effective and affordable while accelerating the development process.